Top

Published in:

Open Access 01-08-2017 | Review

Posterior reversible encephalopathy syndrome

Authors: Marlene Fischer, Erich Schmutzhard

Published in: Journal of Neurology | Issue 8/2017

Abstract

The posterior reversible encephalopathy syndrome (PRES) is a neurological disorder of (sub)acute onset characterized by varied neurological symptoms, which may include headache, impaired visual acuity or visual field deficits, disorders of consciousness, confusion, seizures, and focal neurological deficits. In a majority of patients the clinical presentation includes elevated arterial blood pressure up to hypertensive emergencies. Neuroimaging, in particular magnetic resonance imaging, frequently shows a distinctive parieto-occipital pattern with a symmetric distribution of changes reflecting vasogenic edema. PRES frequently develops in the context of cytotoxic medication, (pre)eclampsia, sepsis, renal disease or autoimmune disorders. The treatment is symptomatic and is determined by the underlying condition. The overall prognosis is favorable, since clinical symptoms as well as imaging lesions are reversible in most patients. However, neurological sequelae including long-term epilepsy may persist in individual cases.

Fugate JE, Rabinstein AA (2015) Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol 14(9):914–925. doi:10.1016/S1474-4422(15)00111-8 CrossRefPubMed

Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29(6):1036–1042. doi:10.3174/ajnr.A0928 CrossRefPubMed

Lee VH, Wijdicks EF, Manno EM, Rabinstein AA (2008) Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 65(2):205–210. doi:10.1001/archneurol.2007.46 CrossRefPubMed

Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR (1996) A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334(8):494–500. doi:10.1056/NEJM199602223340803 CrossRefPubMed

Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA (2010) Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 85(5):427–432. doi:10.4065/mcp.2009.0590 CrossRefPubMedPubMedCentral

Yamamoto H, Natsume J, Kidokoro H, Ishihara N, Suzuki M, Tsuji T, Kubota T, Yamada A, Ozeki M, Kato Z, Kawamura Y, Yoshikawa T, Okumura A, Ando N, Saitoh S, Takahashi Y, Watanabe K, Kojima S (2015) Clinical and neuroimaging findings in children with posterior reversible encephalopathy syndrome. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc 19(6):672–678. doi:10.1016/j.ejpn.2015.07.005 CrossRef

Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29(6):1043–1049. doi:10.3174/ajnr.A0929 CrossRefPubMed

Strandgaard S, Olesen J, Skinhoj E, Lassen NA (1973) Autoregulation of brain circulation in severe arterial hypertension. Br Med J 1(5852):507–510CrossRefPubMedPubMedCentral

Lassen NA (1971) Regulation of cerebral circulation. Acta Anaesthesiol Scand Suppl 45:78–80CrossRefPubMed

10.

Meng L, Gelb AW (2015) Regulation of cerebral autoregulation by carbon dioxide. Anesthesiology 122(1):196–205. doi:10.1097/ALN.0000000000000506 CrossRefPubMed

11.

Kontos HA, Wei EP, Navari RM, Levasseur JE, Rosenblum WI, Patterson JL Jr (1978) Responses of cerebral arteries and arterioles to acute hypotension and hypertension. Am J Physiol 234(4):H371–H383PubMed

12.

MacKenzie ET, Strandgaard S, Graham DI, Jones JV, Harper AM, Farrar JK (1976) Effects of acutely induced hypertension in cats on pial arteriolar caliber, local cerebral blood flow, and the blood-brain barrier. Circ Res 39(1):33–41CrossRefPubMed

13.

Feske SK (2011) Posterior reversible encephalopathy syndrome: a review. Semin Neurol 31(2):202–215. doi:10.1055/s-0031-1277990 CrossRefPubMed

14.

Bartynski WS, Boardman JF, Zeigler ZR, Shadduck RK, Lister J (2006) Posterior reversible encephalopathy syndrome in infection, sepsis, and shock. AJNR Am J Neuroradiol 27(10):2179–2190PubMed

15.

Lamy C, Oppenheim C, Mas JL (2014) Posterior reversible encephalopathy syndrome. Handb Clin Neurol 121:1687–1701. doi:10.1016/B978-0-7020-4088-7.00109-7 CrossRefPubMed

16.

Mayama M, Uno K, Tano S, Yoshihara M, Ukai M, Kishigami Y, Ito Y, Oguchi H (2016) Incidence of posterior reversible encephalopathy syndrome in eclamptic and patients with preeclampsia with neurologic symptoms. Am J Obstet Gynecol 215(2):239 e231–239 e235. doi:10.1016/j.ajog.2016.02.039 CrossRef

17.

Marra A, Vargas M, Striano P, Del Guercio L, Buonanno P, Servillo G (2014) Posterior reversible encephalopathy syndrome: the endothelial hypotheses. Med Hypotheses 82(5):619–622. doi:10.1016/j.mehy.2014.02.022 CrossRefPubMed

18.

Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW (2008) Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 29(5):924–930. doi:10.3174/ajnr.A0960 CrossRefPubMed

19.

Masetti R, Cordelli DM, Zama D, Vendemini F, Biagi C, Franzoni E, Pession A (2015) PRES in children undergoing hematopoietic stem cell or solid organ transplantation. Pediatrics 135(5):890–901. doi:10.1542/peds.2014-2325 CrossRefPubMed

20.

Wu Q, Marescaux C, Wolff V, Jeung MY, Kessler R, Lauer V, Chen Y (2010) Tacrolimus-associated posterior reversible encephalopathy syndrome after solid organ transplantation. Eur Neurol 64(3):169–177. doi:10.1159/000319032 CrossRefPubMed

21.

Hammerstrom AE, Howell J, Gulbis A, Rondon G, Champlin RE, Popat U (2013) Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. Am J Hematol 88(4):301–305. doi:10.1002/ajh.23402 CrossRefPubMed

22.

Reinohs M, Straube T, Baum P, Berrouschot J, Wagner A (2002) Recurrent reversible cerebral edema after long term immunosuppression with tacrolimus. J Neurol 249(6):780–781CrossRefPubMed

23.

Wong R, Beguelin GZ, de Lima M, Giralt SA, Hosing C, Ippoliti C, Forman AD, Kumar AJ, Champlin R, Couriel D (2003) Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol 122(1):128–134CrossRefPubMed

24.

Saner F, Gu Y, Minouchehr S, Ilker K, Fruhauf NR, Paul A, Radtke A, Dammann M, Katsarava Z, Koeppen S, Malago M, Broelsch CE (2006) Neurological complications after cadaveric and living donor liver transplantation. J Neurol 253(5):612–617. doi:10.1007/s00415-006-0069-3 CrossRefPubMed

25.

Bechstein WO (2000) Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int Off J Eur Soc Organ Transplant 13(5):313–326CrossRef

26.

Gijtenbeek JM, van den Bent MJ, Vecht CJ (1999) Cyclosporine neurotoxicity: a review. J Neurol 246(5):339–346CrossRefPubMed

27.

Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, Higuchi S, Otsubo K, Sugimachi K (2002) Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene. Transplantation 74(4):571–572CrossRefPubMed

28.

Liman TG, Bohner G, Heuschmann PU, Endres M, Siebert E (2012) The clinical and radiological spectrum of posterior reversible encephalopathy syndrome: the retrospective Berlin PRES study. J Neurol 259(1):155–164. doi:10.1007/s00415-011-6152-4 CrossRefPubMed

29.

Kastrup O, Gerwig M, Frings M, Diener HC (2012) Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol 259(7):1383–1389. doi:10.1007/s00415-011-6362-9 CrossRefPubMed

30.

Kozak OS, Wijdicks EF, Manno EM, Miley JT, Rabinstein AA (2007) Status epilepticus as initial manifestation of posterior reversible encephalopathy syndrome. Neurology 69(9):894–897. doi:10.1212/01.wnl.0000269780.45472.16 CrossRefPubMed

31.

Burnett MM, Hess CP, Roberts JP, Bass NM, Douglas VC, Josephson SA (2010) Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors. Clin Neurol Neurosurg 112(10):886–891. doi:10.1016/j.clineuro.2010.07.023 CrossRefPubMed

32.

McKinney AM, Short J, Truwit CL, McKinney ZJ, Kozak OS, SantaCruz KS, Teksam M (2007) Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings. AJR Am J Roentgenol 189(4):904–912. doi:10.2214/AJR.07.2024 CrossRefPubMed

33.

de Havenon A, Joos Z, Longenecker L, Shah L, Ansari S, Digre K (2014) Posterior reversible encephalopathy syndrome with spinal cord involvement. Neurology 83(22):2002–2006. doi:10.1212/WNL.0000000000001026 CrossRefPubMed

34.

Neeb L, Hoekstra J, Endres M, Siegerink B, Siebert E, Liman TG (2016) Spectrum of cerebral spinal fluid findings in patients with posterior reversible encephalopathy syndrome. J Neurol 263(1):30–34. doi:10.1007/s00415-015-7928-8 CrossRefPubMed

35.

Datar S, Singh TD, Fugate JE, Mandrekar J, Rabinstein AA, Hocker S (2015) Albuminocytologic dissociation in posterior reversible encephalopathy syndrome. Mayo Clin Proc 90(10):1366–1371. doi:10.1016/j.mayocp.2015.07.018 CrossRefPubMed

36.

Chardain A, Mesnage V, Alamowitch S, Bourdain F, Crozier S, Lenglet T, Psimaras D, Demeret S, Graveleau P, Hoang-Xuan K, Levy R (2016) Posterior reversible encephalopathy syndrome (PRES) and hypomagnesemia: a frequent association? Rev Neurol 172(6–7):384–388. doi:10.1016/j.neurol.2016.06.004 CrossRefPubMed

37.

Gao B, Yu BX, Li RS, Zhang G, Xie HZ, Liu FL, Lv C (2015) Cytotoxic edema in posterior reversible encephalopathy syndrome: correlation of MRI features with serum albumin levels. AJNR Am J Neuroradiol 36(10):1884–1889. doi:10.3174/ajnr.A4379 CrossRefPubMed

38.

Pirker A, Kramer L, Voller B, Loader B, Auff E, Prayer D (2011) Type of edema in posterior reversible encephalopathy syndrome depends on serum albumin levels: an MR imaging study in 28 patients. AJNR Am J Neuroradiol 32(3):527–531. doi:10.3174/ajnr.A2332 CrossRefPubMed

39.

Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28(7):1320–1327. doi:10.3174/ajnr.A0549 CrossRefPubMed

40.

Karia SJ, Rykken JB, McKinney ZJ, Zhang L, McKinney AM (2016) Utility and significance of gadolinium-based contrast enhancement in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 37(3):415–422. doi:10.3174/ajnr.A4563 CrossRefPubMed

41.

McKinney AM, Sarikaya B, Gustafson C, Truwit CL (2012) Detection of microhemorrhage in posterior reversible encephalopathy syndrome using susceptibility-weighted imaging. AJNR Am J Neuroradiol 33(5):896–903. doi:10.3174/ajnr.A2886 CrossRefPubMed

42.

Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, Holman BL (1992) Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 159(2):379–383. doi:10.2214/ajr.159.2.1632361 CrossRefPubMed

43.

Brubaker LM, Smith JK, Lee YZ, Lin W, Castillo M (2005) Hemodynamic and permeability changes in posterior reversible encephalopathy syndrome measured by dynamic susceptibility perfusion-weighted MR imaging. AJNR Am J Neuroradiol 26(4):825–830PubMed

44.

Tajima Y, Isonishi K, Kashiwaba T, Tashiro K (1999) Two similar cases of encephalopathy, possibly a reversible posterior leukoencephalopathy syndrome: serial findings of magnetic resonance imaging, SPECT and angiography. Intern Med 38(1):54–58CrossRefPubMed

45.

Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D (2015) Reversible cerebral vasoconstriction syndrome, part 2: diagnostic work-up, imaging evaluation, and differential diagnosis. AJNR Am J Neuroradiol 36(9):1580–1588. doi:10.3174/ajnr.A4215 CrossRefPubMed

46.

Miller TR, Shivashankar R, Mossa-Basha M, Gandhi D (2015) Reversible cerebral vasoconstriction syndrome, part 1: epidemiology, pathogenesis, and clinical course. AJNR Am J Neuroradiol 36(8):1392–1399. doi:10.3174/ajnr.A4214 CrossRefPubMed

47.

Granata G, Greco A, Iannella G, Granata M, Manno A, Savastano E, Magliulo G (2015) Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 14(9):830–836. doi:10.1016/j.autrev.2015.05.006 CrossRefPubMed

48.

Pak KJ, Hu T, Fee C, Wang R, Smith M, Bazzano LA (2014) Acute hypertension: a systematic review and appraisal of guidelines. Ochsner J 14(4):655–663PubMedPubMedCentral

49.

James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, Lackland DT, LeFevre ML, MacKenzie TD, Ogedegbe O, Smith SC Jr, Svetkey LP, Taler SJ, Townsend RR, Wright JT Jr, Narva AS, Ortiz E (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311(5):507–520. doi:10.1001/jama.2013.284427 CrossRefPubMed

50.

Brickman AM, Reitz C, Luchsinger JA, Manly JJ, Schupf N, Muraskin J, DeCarli C, Brown TR, Mayeux R (2010) Long-term blood pressure fluctuation and cerebrovascular disease in an elderly cohort. Arch Neurol 67(5):564–569. doi:10.1001/archneurol.2010.70 CrossRefPubMedPubMedCentral

51.

Singer S, Grommes C, Reiner AS, Rosenblum MK, DeAngelis LM (2015) Posterior reversible encephalopathy syndrome in patients with cancer. Oncologist 20(7):806–811. doi:10.1634/theoncologist.2014-0149 CrossRefPubMedPubMedCentral

52.

Budhoo A, Mody GM (2015) The spectrum of posterior reversible encephalopathy in systemic lupus erythematosus. Clin Rheumatol 34(12):2127–2134. doi:10.1007/s10067-015-3055-2 CrossRefPubMed

53.

Hinduja A, Habetz K, Raina S, Ramakrishnaiah R, Fitzgerald RT (2016) Predictors of poor outcome in patients with posterior reversible encephalopathy syndrome. Int J Neurosci 1–10. doi:10.3109/00207454.2016.1152966

54.

Tambasco N, Mastrodicasa E, Salvatori C, Mancini G, Romoli M, Caniglia M, Calabresi P, Verrotti A (2016) Prognostic factors in children with PRES and hematologic diseases. Acta Neurol Scand 134(6):474–483. doi:10.1111/ane.12570 CrossRefPubMed

55.

Khan RB, Sadighi ZS, Zabrowski J, Gajjar A, Jeha S (2016) Imaging patterns and outcome of posterior reversible encephalopathy syndrome during childhood cancer treatment. Pediatr Blood Cancer 63(3):523–526. doi:10.1002/pbc.25790 CrossRefPubMed

56.

Sha Z, Moran BP, McKinney AMt, Henry TR (2015) Seizure outcomes of posterior reversible encephalopathy syndrome and correlations with electroencephalographic changes. Epilepsy Behav E&B 48:70–74. doi:10.1016/j.yebeh.2015.05.027 CrossRef

57.

Heo K, Cho KH, Lee MK, Chung SJ, Cho YJ, Lee BI (2016) Development of epilepsy after posterior reversible encephalopathy syndrome. Seizure 34:90–94. doi:10.1016/j.seizure.2015.12.005 CrossRefPubMed

58.

Zweifel C, Dias C, Smielewski P, Czosnyka M (2014) Continuous time-domain monitoring of cerebral autoregulation in neurocritical care. Med Eng Phys 36(5):638–645. doi:10.1016/j.medengphy.2014.03.002 CrossRefPubMed

Title: Posterior reversible encephalopathy syndrome
Authors: Marlene Fischer
Erich Schmutzhard
Publication date: 01-08-2017
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 8/2017
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-016-8377-8

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Posterior reversible encephalopathy syndrome

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

Intermediate Charcot–Marie–Tooth disease: an electrophysiological reappraisal and systematic review

Revisiting mitochondrial ocular myopathies: a study from the Italian Network

Andreas Vesalius (1514–1564)

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study

Teofil Simchowicz (1879–1957)

The role of TSPO PET in assessing neuroinflammation